Pasi A. Jänne, MD, PhD, and Yi-Long Wu, MD, FACS, compare first-line EGFR-mutated NSCLC care in the US and China and discuss SAFFRON and SANOVO.
Yi-Long Wu, MD, FACS
Advertisement
Articles by Yi-Long Wu, MD, FACS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5